Submitted by Anonymous (not verified) on 2 July 2026 - 12:00
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 8, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Date of authorisation: 03/06/2022, Revision: 8, Status: Authorised